BCL6 and diffuse large B-cell lymphoma: The clinical significance of MYC and BCL2 and/or BCL6 rearrangement for patients with DLBCL has been well elucidated; these rearrangements promote highly aggressive clinical behaviour with resistance to standard chemotherapy and extremely poor outcomes [6, 8].